Dynamic Changes of Blood Lipids in Breast Cancer Patients After (Neo)adjuvant Chemotherapy: A Retrospective Observational Study

Figures & data

Table 1 Participants’ Demographics and Baseline Characteristics

	Breast Cancer Patients (n=159)	Controls (n=159)	P
Age (years)	48.42±9.86	48.71±9.10	0.892
BMI (kg/m^2)	24.22±4.12	22.19±3.27	<0.05
Premenopausal (n, %)	61 (38.4)	64 (40.2)	0.818
Smoking (n, %)	9 (5.7)	7 (4.4)	0.798
Alcohol drinking (n, %)	21 (13.2)	17 (10.7)	0.604
Stage of breast cancer
I	50 (31.4)	–	–
II	73 (45.9)	–	–
III	36 (22.6)	–	–
IV	0	–	–
Chemotherapy regimens
TAC	108 (67.9)	–	–
AC-T	46 (28.9)	–	–
CEF	5 (3.1)	–	–
Beast surgery		–	–
Lumpectomy	65 (40.9)	–	–
Mastectomy	94 (59.1)	–	–
HER-2 status
Positive	49 (30.8)	–	–
ER status
Positive	98 (61.6)	–	–

Notes: P<0.05 was regarded as statistically significant. Continuous variables were compared with two-sampled Student’s t-test and categorical variables were compared with χ² test.

Abbreviations: BMI, body mass index; TAC, docetaxel, doxorubicin, cyclophosphamide; AC-T, doxorubicin, cyclophosphamide, docetaxel; CEF, 5-fluorouracil, epirubicin, cyclophosphamide; HER-2, human epidermal growth factor receptor-2; ER, estrogen receptor.

Table 2 The Change of Blood Lipid Profiles Before and After (Neo)adjuvant Chemotherapy in Breast Cancer Patients and Controls

Blood Lipid Profiles	Before Chemotherapy	The 1st Month after Chemotherapy	The 12th Month after Chemotherapy
	Breast cancer patients (n=159)
TC (mmol/L)	4.52±0.87	4.91±0.72*	4.67±0.98
HDL-C (mmol/L)	1.29±1.08	1.32±1.17	1.27±0.84
LDL-C (mmol/L)	1.59±0.42	2.32±0.31*	1.82±0.42*
TG (mmol/L)	2.82±0.63	3.27±0.92*	2.98±0.71*
	Controls (n=159)
TC (mmol/L)	4.57±0.89	4.58±0.92	4.54±0.87
HDL-C (mmol/L)	1.21±0.98	1.27±0.92	1.24±0.93
LDL-C (mmol/L)	1.54±0.57	1.52±0.64	1.49±0.73
TG (mmol/L)	2.80±0.73	2.78±0.84	2.81±0.76

Notes: *P<0.05 vs the value before chemotherapy. The data were compared with a single-sample Student’s t-test or non-parametric tests based on the distributional properties.

Abbreviations: TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Table 3 The Change of Dyslipidemia Percentage Before and After (Neo)adjuvant Chemotherapy According to Age, BMI, and Chemotherapy Regimens

Percentage of Dyslipidemia (n=159)	Before Chemotherapy	The 1st Month after Chemotherapy	The 12th Month after Chemotherapy
All	66 (41.5)	103 (64.8)*	86 (54.1)*
Age stratification
20–39 years (n=34)	8 (23.5)	14 (41.2)	6 (17.6)
40–49 years (n=78)	28 (35.9)	45 (57.7)*	41 (52.6)
≥50 years (n=47)	30 (63.8)	44 (93.6)*	39 (83.0)
BMI stratification
<18 kg/m^2(n=20)	3 (15.0)	11 (55.0)*	8 (40.0)
18–24 kg/m^2(n=83)	32 (38.6)	49 (59.0)*	41 (49.4)
≥24 kg/m^2(n=56)	31 (55.4)	43 (76.8)*	37 (66.1)
Chemotherapy regimens
TAC (n=108)	41 (38.0)	67 (62.0)*	57 (52.8)*
AC-T (n=46)	25 (54.3)	36 (78.3)*	29 (63.0)

Notes: *P<0.05 vs the value before chemotherapy. The data were compared with χ² test.

Abbreviations: BMI, body mass index; TAC, docetaxel, doxorubicin, and cyclophosphamide, cycled every 3 weeks for six cycles; AC-T, doxorubicin and cyclophosphamide, cycled every 3 weeks for four cycles, followed by docetaxel, cycled every 3 weeks for four cycles.